TriSalus Life Sciences (TLSI)
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics t...
- Open
- 5.740
- High
- 5.760
- Low
- 5.520
- Prev. Close
- 5.740
- Volume
- 12.75K
- Turnover
- 72.81K
- Avg Price
- 5.712
- Bid/Ask Ratio
- 46.34%
- Amplitude
- 4.18%
- 52wk High
- 7.950
- Volume Ratio
- 0.65
- Turnover Ratio
- 0.03%
TriSalus Life Sciences Analyst Rating
View moreForecast & Rating
Aug 10, 2026Price forecast
$10.0074.22%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 1 day ago, 11:25 AM
Analyst Justin Walsh Reaffirms Buy on TriSalus After Strong Q2 Results, CMS Reimbursement Tailwinds, and Growth Outlook Through 2026
- Market Beat · Aug 7 at 12:04 AM
NerdWallet Q2 Earnings Call Highlights
- Earnings Watch · Aug 6 at 03:15 PM
TriSalus Life Sciences | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 11.41 M
- PUBT · Aug 6 at 03:11 PM
TriSalus Q2 FY26 net loss narrows 40.74% to $0.16 per share; revenue rises 1.7% to $11.4 million
- PUBT · Jul 29 at 03:13 PM
TriSalus Life Sciences to join Canaccord Genuity Annual Growth Conference fireside chat
- PUBT · Jun 29 at 03:31 PM
TriSalus Life Sciences names Richard Henry Marshall as chief medical officer in initial beneficial ownership filing
